GRANULES.NSE News

In this briefing: Sharda Cropchem - Continuing Momentum Despite Geopolitical Tantrums Primer: Anthem Biosciences (1234D IN) - Apr 2026 Amagi Media Labs: Taking Media Companies to the Cloud Universe Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins 1. Sharda Cropchem - Continuing Momentum Despite Geopolitical Tantrums Sharda Cropchem is an asset-light agrochemical supplier that sources products mainly from China and India, sells globally, and builds competitive advantage through extensive regulatory product registrations instead of manufacturing capabilities. They invest heavily in product registrations, creating large pipeline that converts into revenue over time, driving strong cash flows funding growth internally, and supporting dividends despite high accounting amortization charges. Sharda’s massive registration pipeline and presence in regulated markets drive growth despite sourcing and forex risks.

In this briefing: Primer: Anthem Biosciences (1234D IN) - Apr 2026 Amagi Media Labs: Taking Media Companies to the Cloud Universe Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins Gold Loan: How a Collateral-First Product Became India's Largest Retail Loan 1. Primer: Anthem Biosciences (1234D IN) - Apr 2026 Anthem Biosciences is a fully integrated Contract Research, Development, and Manufacturing Organization (CRDMO) providing end-to-end services for small and large molecules to the global pharmaceutical and biotechnology sectors. The company has demonstrated a strong financial track record, with a 32% CAGR in operating revenue between FY23 and FY25, and boasts industry-leading EBITDA margins. Key growth drivers include its leadership in fermentation capacity in India, expertise in advanced therapeutic modalities like ADCs and RNAi, and a strategic focus on backward integration to reduce reliance on external suppliers.

In this briefing: Amagi Media Labs: Taking Media Companies to the Cloud Universe Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins Gold Loan: How a Collateral-First Product Became India's Largest Retail Loan The Adani Group Clearance: Deconstructing the CCI Verdict and What It Means for the Conglomerate 1. Amagi Media Labs: Taking Media Companies to the Cloud Universe Amagi's unified cloud-based media infrastructure serves to digitise traditional media content and enable monetisation. Its two-way platform supports not just the content-owners but also distributors globally with varied content access By attracting both media companies and distributors, Amagi benefits from a content-driven flywheel effect, creating structural stickiness with 120+% NRR and 35–50% cost savings for broadcasters. Amagi has been a key enabler for broadcasting for live-events (FIFA, NFL) while its content library attracts small/new OTT platforms.

In this briefing: Approaches Aimed at Resolving “parent-Subsidiary Listings” in the Broad Sense Remain Effective Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) HEW: Rallying into the Void Japan Strategy Weekly Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins 1. Approaches Aimed at Resolving “parent-Subsidiary Listings” in the Broad Sense Remain Effective A common challenge faced by Japanese companies is inability to concentrate resources on businesses with high profit margins and growth potential, resulting in failure to successfully expand promising businesses overseas. Establishing and implementing clear criteria for deciding when to invest in or withdraw from businesses is essential for restructuring the business portfolio. The litmus test is eliminating parent-subsidiary dual listings. The Standard Market is likely to become the main battleground for efforts to resolve parent-subsidiary dual listings.In the Prime Market, increased approaches from activist investors targeting equity-method affiliates are inevitable. 2.

In this briefing: Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) HEW: Rallying into the Void Japan Strategy Weekly Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins The Stocks to Own in China – Vol. 39 1. Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Downstream oil products remain elevated, yet oil futures continue to soften. GCC states say that it will take years to rebuild and replace some infrastructure. The petrodollar has taken a hit as Gulf countries are selling less oil and emerging markets are forced to sell dollars to plug deficits caused by higher oil prices. The petroyuan is gaining traction as the Middle East conflict has rerouted some payments through the Chinese CIPS and mBridge networks. 2. HEW: Rallying into the Void No news was good enough news for risk assets to keep rallying, but even a benign end to the US-Iran war will not negate the inflation shock lifting policy rates. EA inflation recovered some of its downside surprise in its final March print, but the UK’s international stature can’t recover.

In this briefing: Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins Gold Loan: How a Collateral-First Product Became India's Largest Retail Loan The Adani Group Clearance: Deconstructing the CCI Verdict and What It Means for the Conglomerate Primer: Cipla Ltd (CIPLA IN) - Apr 2026 1. Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Downstream oil products remain elevated, yet oil futures continue to soften. GCC states say that it will take years to rebuild and replace some infrastructure. The petrodollar has taken a hit as Gulf countries are selling less oil and emerging markets are forced to sell dollars to plug deficits caused by higher oil prices. The petroyuan is gaining traction as the Middle East conflict has rerouted some payments through the Chinese CIPS and mBridge networks. 2. Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins US Paracetamol prices jumped 24.6% MoM in March 2026 , driven by post-Lunar New Year Chinese supply pullback, Indian facility FDA alerts & surging para-aminophenol cost.

In this briefing: HEW: Rallying into the Void Japan Strategy Weekly Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins The Stocks to Own in China – Vol. 39 CX Daily: ByteDance’s Billion-Yuan Bet on China’s First AI-Native Hospital? 1. HEW: Rallying into the Void No news was good enough news for risk assets to keep rallying, but even a benign end to the US-Iran war will not negate the inflation shock lifting policy rates. EA inflation recovered some of its downside surprise in its final March print, but the UK’s international stature can’t recover. It failed to defend its investing allies. Next week is packed with news for the UK, where the rise in its inflation data is our highlight, with its labour market and global flash PMIs other notable releases. 2. Japan Strategy Weekly Japanese equities posted a modest gain this week, with the Topix Index rising +0.6% and extending its year-to-date advance to +10.3%. The move came against a supportive global backdrop, as U.S. markets rallied strongly— Nasdaq climbed ~4%—helping sustain risk appetite despite pockets of volatility.

In this briefing: Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins The Stocks to Own in China – Vol. 39 CX Daily: ByteDance’s Billion-Yuan Bet on China’s First AI-Native Hospital? The Adani Group Clearance: Deconstructing the CCI Verdict and What It Means for the Conglomerate Samsung Electronics - Pays Out Special Dividend & Consensus Likely to Raise DPS by 30%+ for 2026 1. Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins US Paracetamol prices jumped 24.6% MoM in March 2026 , driven by post-Lunar New Year Chinese supply pullback, Indian facility FDA alerts & surging para-aminophenol cost. Indian API-heavy players like Granules India, Aurobindo, Dr. Reddy's & IPCA face squeeze of input costs & restricted supply of exports , compressing EBITDA when the US pharma tariff threat looms. Integrated giants like Sun Pharma & Cipla have buffers; pure-play API and formulation players like Granules India are most exposed. This situation is worth tracking closely heading into FY26 earnings. 2.

In this briefing: Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins Gold Loan: How a Collateral-First Product Became India's Largest Retail Loan The Adani Group Clearance: Deconstructing the CCI Verdict and What It Means for the Conglomerate Primer: Cipla Ltd (CIPLA IN) - Apr 2026 Primer: Indus Towers (INDUSTOW IN) - Apr 2026 1. Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins US Paracetamol prices jumped 24.6% MoM in March 2026 , driven by post-Lunar New Year Chinese supply pullback, Indian facility FDA alerts & surging para-aminophenol cost. Indian API-heavy players like Granules India, Aurobindo, Dr. Reddy's & IPCA face squeeze of input costs & restricted supply of exports , compressing EBITDA when the US pharma tariff threat looms. Integrated giants like Sun Pharma & Cipla have buffers; pure-play API and formulation players like Granules India are most exposed. This situation is worth tracking closely heading into FY26 earnings. 2. Gold Loan: How a Collateral-First Product Became India's Largest Retail Loan Gold loans have overtaken home loans by origination value, reaching ~39% of retail disbursals as of December 2025, with the portfolio growing 4x since March 2022 to ~INR3.38 lakh crore.